A peer-reviewed Formal Comment by Prof. Backert and colleagues discussing results relating to this work has been published as Tegtmeyer N, Lind J, Schmid B, Backert S (2014) Helicobacter pylori CagL Y58/E59 Mutation Turns-Off Type IV Secretion-Dependent Delivery of CagA into Host Cells. PLOS ONE 9(6): e97782. doi:10.1371/journal.pone.0097782

Following discussion among Associate Editor Matt Hodgkinson, the authors, and the handling editor Jun Sun, and in response to the issues raised in the Formal Comment, we are posting a correction to address: 1) confirmation of the strain mutations by PCR, sequencing, and RT-PCR; 2) clarification of the availability of the strains.

The authors have provided DNA sequencing and RT-PCR data in supporting information files:

[Figure S1](#pone.0101912.s002){ref-type="supplementary-material"} shows a diagram of the construction of the *cagL* mutant (A), revertant, and amino acid replacement mutants (B).

[Figure S2](#pone.0101912.s003){ref-type="supplementary-material"} confirms the *cagL* mutant, revertant, and amino acid replacement mutants using PCR.

[Figure S3](#pone.0101912.s004){ref-type="supplementary-material"} shows sequencing results of *H. pylori* clinical strain Hp1033 wild type, *cagL* insertion mutant, revertant, and amino acid replacement mutants.

[Figure S4](#pone.0101912.s005){ref-type="supplementary-material"} shows RT-PCR of *cagL* expression for Hp1033 wild type, *cagL* mutant and replacement mutants co-cultured with AGS cells at pH 7.4 for 1 hour.

[Table S1](#pone.0101912.s001){ref-type="supplementary-material"} shows the primers used for sequencing and RT-PCR.

The authors have no Anti-*CagL* antibody, and so they are not able to show protein expression.

Sharing of the strains/isolates of *H. pylori* reported in the manuscript may be done following a formal request. This application is necessary to comply with the regulatory processes in the authors\' institution and the customs/export regulations between Taiwan and other countries.
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###### 

Primers used for sequencing and RT-PCR.

###### 

Click here for additional data file.

###### 

The diagram of construction of *cagL* mutant (A), revertant, and amino acid replacement mutants (B).

###### 

Click here for additional data file.

###### 

Confirming *cagL* mutant, revertant, and amino acid replacement mutants by using PCR. PCR Amplicons from wild type, revertants, and amino acid replacement mutants are 1.1kb (using primer cagL-5 & cagL-6) or 1.4kb (using primer cagIL-1 & cagL-6), from *cagL* insertion mutants are 2kb. (A) M: marker; w: Hp1033 wild type; lane1-16: Hp1033 *cagL::cat*. (B) lane1-12: 26695 *cagL::cat*; lane 13-23: J99 *cagL::cat*; lane 24: Hp1033 *cagL*-Y58/E59 revertant. (C) lane 25-29: Hp1033 *cagL*-Y58D/E59 amino acid replacement mutants; lane 30: Hp1033 *cagL::cat* ; lane 31: Hp1035 *cagL::cat*. (D) lane 32-35: Hp1033 *cagL*-Y58/E59K amino acid replacement mutants. (E) lane 36-39: Hp1033 *cagL*-Y58D/E59K amino acid replacement mutants ; lane 40: Hp1035 *cagL*-Y58D/E59K amino acid replacement mutants. Arrows indicate the clones selected in this study.

###### 

Click here for additional data file.

###### 

The sequencing results of *H. pylori* clinical strain Hp1033 wild type, *cagL* insertion mutant, revertant, and amino acid replacement mutants. Multiple Alignments were processed by MAFFT L-INS-1 (v6.850b) from EMBL-EBI website. The blue blocks indicate the region of chloramphenicol resistance gene. The yellow block indicates the position of amino acid 58 and 59 residues.

###### 

Click here for additional data file.

###### 

After Hp1033 wild type, *cagL* mutant and replacement mutants co-cultured with AGS cells at pH 7.4 for 1 hour, cagL expression was examined by RT-PCR. There was no difference in CagL expressions among Hp1033 wild type, revertant, and amino acid replacement mutants. The 3rd lane indicated there was no RNA contamination.

###### 

Click here for additional data file.
